<DOC>
	<DOCNO>NCT01258816</DOCNO>
	<brief_summary>The purpose study investigate pharmacokinetics ( PK ) cardiac property elacytarabine patient relapse refractory Acute Myeloid Leukaemia ( AML ) . The efficacy tolerability elacytarabine also assess .</brief_summary>
	<brief_title>The Pharmacokinetics Cardiac Properties Elacytarabine ( CP-4055 )</brief_title>
	<detailed_description>Elacytarabine investigational drug commercially available . It consist fatty acid connect cytarabine commonly use treatment AML . Due connection fatty acid , elacytarabine might increase uptake blast cell thereby increase efficacy . The characterisation pharmacokinetics investigational drug , well cardiac safety essential . The PK elacytarabine metabolite assess defined timepoints , infusion . The cardiac safety elacytarabine evaluate triplicate ECG recording time point PK assessment . Elacytarabine give continuous infusion 5 day . The patient may continue course elacytarabine long patient benefit treatment elacytarabine .</detailed_description>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>Inclusion¨Criteria : 1 . Patients must relapse / refractory AML accord WHO classification ( exclude acute promyelocytic leukaemia ) 2 . Patients must ECOG Performance Status ( PS ) 0 2 3 . Patients must 18 year age old 4 . Women childbearing potential must negative serum urine pregnancy test within two week prior treatment start 5 . Male female fertile patient must use adequate contraception duration study , male also 3 month last elacytarabine dose 6 . Patients must capable understand comply protocol requirement , must able willing sign write informed consent 1 . A history allergic reaction egg . A history CTCAE grade 3 4 allergic reaction araC 2 . A history cancer accord investigator might confound assessment endpoint clinical study 3 . Known positive status human immunodeficiency virus ( HIV ) 4 . Pregnant nursing patient 5 . Uncontrolled intercurrent illness include , limited , uncontrolled infection , psychiatric illness/social situation limit compliance study requirement 6 . Impairment hepatic renal function extent patient , opinion investigator , expose excessive risk enter clinical study 7 . Active heart disease include myocardial infarction within previous 3 month , symptomatic coronary artery disease , arrhythmias control medication , uncontrolled congestive heart failure . Any NYHA grade 3 4 8 . A history familial long QT syndrome 9 . Patients history serious ventricular arrhythmia ( VT VT ) 10 . ECG criterion eligibility visit : QTc ≥ 480 msec calculate use Fridericia ` correction ( QTcF = QT/RRO,33 ) bradycardia ( &lt; 50bpm ) criterion leave ventricular hypertrophy 11. treatment medication know produce QT prolongation 12 . Treatment hydroxyurea 6mercaptopurine within last 12 hour prior treatment protocol investigational standard cytotoxic treatment within last 14 day 9 . Any medical condition opinion investigator place patient unacceptably high risk toxicity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Acute Myeloid Leukaemia ( AML )</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Elacytarabine</keyword>
	<keyword>CP-4055</keyword>
</DOC>